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A B S T R A C T
Background
Heparin intermittent ﬂushing is a standard practice in the maintenance of patency in central venous catheters. However, we could ﬁnd
no systematic review examining its effectiveness and safety.
Objectives
To assess the effectiveness of intermittent ﬂushing with heparin versus 0.9% sodium chloride (normal saline) solution in adults with
central venous catheters in terms of prevention of occlusion and overall beneﬁts versus harms.
Search methods
The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searchedDecember
2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 11). Searches were also carried out in
MEDLINE, EMBASE, CINAHL and clinical trials databases (December 2013).
Selection criteria
Randomised controlled trials (RCTs) in adults 18 years of age and older with a central venous catheter (CVC) in which intermittent
ﬂushing with heparin (any dose with or without other drugs) was compared with 0.9% normal saline were included. No restriction on
language was applied.
Data collection and analysis
Two review authors independently selected trials, assessed trial quality and extracted data. Trial authors were contacted to retrieve
additional information, when necessary.
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Main results
Six eligible studies with a total of 1433 participants were included. The heparin concentrations used in these studies were very different
(10-5000 IU/mL), and follow-up varied from 20 days to 180 days. The overall risk of bias in the studies was low. The quality of the
evidence ranged from very low to moderate for the main outcomes (occlusion of CVC, duration of catheter patency, CVC-related
sepsis, mortality and haemorrhage at any site).
Combined ﬁndings from three trials in which the unit of analysis was the catheter suggest that heparin was associated with reduced CVC
occlusion rates (risk ratio (RR) 0.53, 95% conﬁdence interval (CI) 0.29 to 0.94). However, no clear evidence of a similar effect was
found when the results of two studies in which the unit of analysis was the participant were combined (RR 0.21, 95% CI 0.03 to 1.70),
nor when ﬁndings were derived from one study, which considered total line accesses (RR 1.08, 95% CI 0.84 to 1.40). Furthermore,
results for other estimated effects were found to be imprecise and compatible with beneﬁt and harm: catheter duration in days (mean
difference (MD) 0.41, 95% CI -1.29 to 2.12), CVC-related thrombosis (RR 1.22, 95% CI 0.74 to 1.99), CVC-related sepsis (RR
1.02, 95% CI 0.34 to 3.03), mortality (RR 0.77, 95% CI 0.45 to 1.32) and haemorrhage at any site (RR 1.37, 95% CI 0.49 to 3.85).
Authors’ conclusions
We found no conclusive evidence of important differences when heparin intermittent ﬂushing was compared with 0.9% normal saline
ﬂushing for central venous catheter maintenance in terms of efﬁcacy or safety. As heparin is more expensive than normal saline, our
ﬁndings challenge its continued use in CVC ﬂushing outside the context of clinical trials.
P L A I N L A N G U A G E S U M M A R Y
Heparin versus saline solution flushing for prevention of occlusion in central venous catheters in adults
Central venous catheters (CVCs) are temporary devices implanted into patients when easy or frequent intravenous access is needed.
Doctors often use them. A Hickman line is an example of a CVC. A CVC is used, for instance, for monitoring patients in intensive
care, or for giving chemotherapy or intravenous nutrition. However, such catheters can cause blood clots, which can block the line,
increase the risk of infection and travel elsewhere in the body such as to the lung (this is called thromboembolism). Heparin is a drug
that helps to prevent blood clots and may help prevent these unwanted consequences. But heparin can also cause serious adverse effects
(bleeding, allergic reactions, fall in platelet count, etc.). Normal saline solution, a sterile solution of salt in water at a concentration
suitable for the blood, is typically used for intravenous infusions. We wanted to know whether heparin helps prevent the unwanted
effects of blood clots in CVCs, and if this beneﬁt outweighs its risk of harms.
Six studies with a combined total of 1433 participants were included. The quality of the evidence ranged from very low to moderate
for the main outcomes.
Our review found no compelling evidence of a decrease in the rate of blocking of CVCs ﬂushed with heparin compared with CVCs
ﬂushed with sterile saline solution, nor of differences in the number of days the catheter lasted, the rate of thrombosis, rate of infection,
mortality, bleeding rates or heparin-induced fall in platelet count.
We conclude there is no good evidence that heparin ﬂushing of CVCs is better than ﬂushing with sterile saline solution. As heparin is
more expensive, the ﬁndings of this review do not support its use except in future clinical trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Heparin for central venous catheters
Patient or population: patients with central venous catheters
Settings: adults
Intervention: heparin
Comparison: normal saline (0.9% NaCl)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Heparin
Occlusion of CVC (unit of
analysis-participant)
Blood withdrawing
Follow-up: not reported
Study population RR 0.21
(0.03-1.7)
150
(2 studies)
⊕©©©
very lowa,b,c
53 per 1000 11 per 1000
(2-89)
Moderate
49 per 1000 10 per 1000
(1-83)
Duration of catheter pa-
tency (unit of analysis-
participants)
Blood withdrawing
Follow-up: until 180 days
Mean catheter survival
(unit of analysis partici-
pants) in the intervention
groups was 0.41 higher
(1.29 lower-2.12 higher)
952
(3 studies)
⊕⊕©©
lowd,e
CVC-related sepsis
Positive microbiological
culturef
Follow-up: 1-180 days
Study population RR 1.02
(0.34-3.03)
1097
(2 studies)
⊕⊕⊕©
moderatef
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11 per 1000 11 per 1000
(4-33)
Moderate
16 per 1000 16 per 1000
(5-48)
Mortality
Follow-up: 180 days
Study population RR 0.77
(0.45-1.32)
1100
(3 studies)
⊕⊕⊕©
moderateg
55 per 1000 42 per 1000
(25-72)
Moderate
14 per 1000 11 per 1000
(6-8)
Haemorrhage at any site
Oozing blood from
catheterh
Follow-up: 1-22 daysi
Study population RR 1.37
(0.49-3.85)
1145
(3 studies)
⊕⊕©©
lowj,k
28 per 1000 39 per 1000
(14-109)
Moderate
96 per 1000 132 per 1000
(47-370)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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aTwo trials (Bowers 2008; Kaneko 2004) were rated as unclear risk of bias for insufficient information to permit judgement of allocation
concealment (selection bias).
bHeparin concentration for flushing was different: 100 IU/mL in Bowers 2008 and 1000 IU/mL in Kaneko 2004.
cConfidence intervals in trials were very wide.
dThe 3 trials (Bowers 2008; Goosens 2013; Kaneko 2004) were rated as unclear risk of bias for insufficient information to permit
judgement of allocation concealment (selection bias).
eConfidence intervals were very wide.
fOnly Goosens 2013 stated diagnostic procedures for bloodstream infection.
gFollow-up of 1 trial (Pumarola 2007) was very short for assessment of mortality.
hIn Schallom 2012 bleeding is mentioned, but no data about it were reported.
iReported only in Schallom 2012.
jTrial of Kaneko 2004 was rated as unclear risk of bias for random sequence generation and allocation concealment (selection bias).
kWide confidence intervals in both studies.
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B A C K G R O U N D
Description of the condition
Vascular access devices (VADs) are commonly used in health care.
They encompass a wide range of devices that include, among oth-
ers, central venous catheters (CVCs). A CVC is a catheter with a
tip that lies within the proximal third of the superior vena cava,
the right atrium or the inferior vena cava. Catheters can be in-
serted through a peripheral vein or a proximal central vein, most
commonly the internal jugular, subclavian or femoral vein. Four
types of CVCs are available: non-tunnelled, tunnelled (e.g. Hick-
man catheters, tunnelled dialysis catheters) and peripherally in-
serted catheters and totally implantable ports (port-a-cath) (Smith
2013).
In the United States, more than ﬁve million CVCs are inserted
every year (Merrer 2001), leading to approximately 15 million
central line days per year in intensive care units (ICUs) (Mermel
2000). CVCs allowmeasurement of haemodynamic variables that
cannot bemeasured accurately by non-invasivemethods (although
some minimally invasive methods are now available), and they
allow delivery of blood, medication and nutritional support that
cannot be given safely through peripheral venous catheters. Unfor-
tunately, the use of CVCs is associated with adverse events, among
them mechanical complications during insertion (arterial punc-
ture, haematoma and pneumothorax are the most common me-
chanical complications), infectious complications in 5% to 26%
(Merrer 2001; Raad 1997; Veenstra 1999) and thrombosis in 2%
to 26% (Lee 2007).
To some extent, thrombi are formed on CVCs during the ﬁrst few
hours in the form of ﬁbrin tail, ﬁbrin sheath, intraluminal occlu-
sion or mural thrombus (Jonker 2010), and thrombosis of large
vessels occurs after long-term catheterisation (Valerio 1981). The
incidence of CVC-related thrombosis varies depending, among
others factors, on the patient’s condition, catheter tip position
and diameter, side and technique of insertion and the chemical
structure and nature of the infusate (Verso 2003). CVC-related
thrombosis represents an important source of morbidity and mor-
tality among affected patients, not only for its inherent risks but
also because thrombus creates a medium for bacterial proliferation
that promotes infection (Mermel 2000). Pulmonary embolism,
a severe medical condition, occurs in approximately 15% of pa-
tients with CVC-related upper extremity deep venous thrombosis
(Burns 2008).
To avoid thrombus formation in CVCs, several measures are cur-
rently being applied with different levels of success. Among oth-
ers, heparin ﬂushing (Bishop 2009), heparin-bonded catheters
(Shah 2008), systemic heparinisation with unfractionated heparin
or with low molecular weight heparin (Randolph 1998b), antico-
agulation with warfarin (Bern 1990) or administration of alteplase
(Hemmelgarn 2011) or urokinase (Ray 1999) may be used. Hep-
arin ﬂushing is the most commonly used procedure. According to
some authors, the use of heparin may be justiﬁed with some types
of VADs when they are not used frequently (Bishop 2009); but
the efﬁcacy of this practice is unproven (López-Briz 2005).
Description of the intervention
Heparin ﬂushing essentially consists of ﬁlling the lumens of CVCs
between uses using solutions of unfractionated heparin of varying
strength.
How the intervention might work
Use of CVCs predisposes to vascular thrombosis bymeans of vessel
wall injury (during catheter placement), hypercoagulability and
alterations in normal blood ﬂow. Balance between haemostatic
systems producing thrombi and the ﬁbrinolytic systems dissolv-
ing them regulates blood vessel lumen patency, but placement of
a CVC can alter this ﬁne-tuned process, leading to a persistent
thrombotic state. Catheter composition also plays a role in this
thrombotic situation, allowing adsorption of ﬁbrin and ﬁbrinogen
on its surface and thereby worsening the problem (Jacobs 2003).
The anticoagulant properties of heparin have led clinicians to use
heparin ﬂushes in an attempt to prevent thrombus formation and
to prolong the duration of catheter patency between uses. This
physiopathological rationale, however, may be wrong when ap-
plied to peripheral venous catheters, for which no beneﬁt in using
heparin ﬂushing versus 0.9% NaCl (normal saline) ﬂushing has
been demonstrated, as two published systematic reviews have in-
dependently shown (Goode 1991; Randolph 1998a).
Why it is important to do this review
Heparin ﬂushing is a standard practice in the maintenance of
CVCs (Bishop 2009), but the effectiveness of this practice has not
been established in a systematic review so far. Moreover, variation
in nursing practice is considerable because current guidelines pro-
vide conﬂicting recommendations about ﬂushing frequency and
heparin concentration and volume (Mitchell 2009). A recent sur-
vey conducted in ICUs in the United States (Sona 2012) showed
that 64.6% of respondents used normal saline solution and 31%
used heparin. The most frequent concentrations of heparin used
were 100 IU/mL (37.5%) and 10 IU/mL (29.7%), and the most
frequent intervals for ﬂushing were every eight hours and after
each use (74.4%). No information is available on CVC mainte-
nance practices in other countries, so could clinical expertise be
the guiding principle on this topic?
There are reasons to think that heparin ﬂushing might be helpful.
It makes pathophysiological sense. The systematic review by Ran-
dolph et al. (Randolph 1998b) looking at the beneﬁts of heparin
in central venous and pulmonary artery catheters showed that pro-
phylactic systemicheparin decreases catheter-related venous throm-
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bosis (risk ratio (RR) 0.43, 95% conﬁdence interval (CI) 0.23 to
0.78) and bacterial colonisation of CVCs (RR 0.18, 95% CI 0.06
to 0.60), and may decrease catheter-related bacteraemia (RR 0.26,
95% CI 0.07 to 1.03). Said systematic review included combined
data from trials using several doses of systemic prophylactic hep-
arin, including unfractionated heparin (dose regimens of 1 IU/kg,
3 IU/kg, 50 IU q12h and 5000 IU intermittently), low molecular
weight heparin (2500 IU given subcutaneously daily) or heparin-
bonded catheters. It did not include trials using intermittent ﬂush-
ing of CVCs with heparin.
However, there are also potential harms associated with hep-
arin use. Heparin-induced thrombocytopenia (HIT), a severe im-
munological drug reaction known to cause arterial and venous
thromboembolism without haemorrhage, raises serious concerns
regarding the use of heparin (Warkentin 2007). Exposure of sur-
gical patients to unfractionated heparin for longer than four days
implies an overall risk of HIT of 2.6% (Martel 2005). This adverse
effect of heparin treatment is a typical late-onset complication that
can develop ﬁve or more days after initiation of the drug.
From an economic point of view, avoiding heparin ﬂushing would
represent very important cost savings (Sona 2012). In the above
mentioned systematic review by Goode et al (Goode 1991), yearly
savings of $109 million to $218 million were estimated when
peripheral venous lines were ﬂushed with 0.9% NaCl instead of
heparin.
In summary, the effectiveness of heparin ﬂushing of CVCs has
not yet been demonstrated, and wide systematic variations in both
guideline recommendations and practice have surrounded its use.
Moreover, use of heparin is not free of risk and has a considerable
economic impact. A systematic review is urgently needed.
O B J E C T I V E S
To assess the effectiveness of intermittent ﬂushing with heparin
versus 0.9% sodium chloride (normal saline) solution in adults
with central venous catheters in terms of prevention of occlusion
and overall beneﬁts versus harms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials of heparin ﬂushing
versus ﬂushing of normal saline solution in adults. Studies were
excluded when alternative methods of randomisation (quasi-ran-
domised), such as alternate days of the week, odd and even num-
bers, dates of birth, hospital numbers or historical controls, were
used.
Types of participants
Adults 18 years of age or older with a CVC.
Studies on infants and children were excluded from this review, as
they are the topic of another Cochrane review (Bradford 2014).
Types of interventions
Intermittent ﬂushingwith heparin (any dose with or without other
drugs) compared with 0.9% normal saline solution. All ﬂushing
protocols were acceptable for inclusion.
Types of outcome measures
Primary outcomes
• Occlusion of CVCs (deﬁned as inability to infuse ﬂuids
through the catheter due to a blockage).
• Duration (in days) of catheter patency.
Secondary outcomes
• CVC-related thrombosis (determined by colour-coded
Doppler ultrasonography, venography, computerised
tomography or magnetic resonance venography).
• Episodes of CVC-related sepsis and CVC-related
colonisation. CVC-related sepsis is deﬁned as the presence of
symptoms and signs suggestive of sepsis, accompanied by
positive blood cultures obtained from a normally sterile site
different from the CVC and from the CVC or CVC tip, each
growing the same micro-organism; CVC-related colonisation is
deﬁned as the presence of micro-organisms in the CVC only and
not from another sterile site.
• Number of additional CVC insertions.
• Mortality.
• Abnormality of coagulation proﬁle.
• Allergic reactions to heparin.
• Heparin-induced thrombocytopaenia (HIT) (development
of thrombocytopaenia after heparin ﬂushing of a CVC in an
adult with a previously normal platelet count after exclusion of
all other causes of thrombocytopaenia, along with a positive
antibody test).
• Haemorrhage from any site in the body.
Search methods for identification of studies
No restriction on language of publication was applied.
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Electronic searches
The Cochrane Peripheral Vascular Diseases (PVD) Group Tri-
als Search Co-ordinator (TSC) searched the Specialised Regis-
ter (last searched December 2013) and the Cochrane Central
Register of Controlled Trials (CENTRAL) (2013, Issue 11) (
www.thecochranelibrary.com). See Appendix 1 for details of the
search strategy used to searchCENTRAL.The SpecialisedRegister
is maintained by the TSC and is constructed through weekly elec-
tronic searches of MEDLINE, EMBASE, CINAHL, AMED, and
by handsearching of relevant journals. The full list of databases,
journals and conference proceedings that have been searched and
the search strategies used are presented in the Specialised Register
section of the Cochrane PVDGroupmodule withinThe Cochrane
Library (www.thecochranelibrary.com).
The following trial databaseswere searchedby theTSC (December
2013) for details of ongoing and unpublished studies, using the
terms ’heparin’ and ’catheter.’
• World Health Organization International Clinical Trials
Registry (http://apps.who.int/trialsearch/).
• ClinicalTrials.gov (http://clinicaltrials.gov/).
• Current Controlled Trials (http://www.controlled-
trials.com/).
In addition MEDLINE, EMBASE and CINAHL were searched
using the strategies shown in Appendix 2, Appendix 3 and
Appendix 4.
Searching other resources
The reference lists of relevant studies identiﬁed through the elec-
tronic searches were searched. Authors of unpublished and ongo-
ing trials were contacted to obtain additional data (Goosens 2013;
Schallom 2012).
Data collection and analysis
Selection of studies
Two review authors independently read the abstracts and, if nec-
essary, the full text of potentially relevant references, to identify
studies that needed to be further examined. Letters, editorials,
commentaries, reviews and lectures that did not contain original
research data were excluded. When differences in opinion arose, a
third review author was consulted.
Data extraction and management
For studies fulﬁlling inclusion criteria, three review authors in-
dependently extracted data regarding population, interventions
and relevant outcomes, using the standard Cochrane PVDGroup
forms for dichotomous data and for continuous data.
Assessment of risk of bias in included studies
Risk of bias in included studies was assessed by using standardised
criteria from The Cochrane Collaboration (Higgins 2011) on the
following.
• Adequacy of random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective reporting.
• Other bias.
Measures of treatment effect
Odds ratio (OR), risk ratio (RR) with 95% conﬁdence interval
(CI) and number needed to treat for an additional beneﬁcial out-
come (NNTB) were used to analyse dichotomous variables (i.e.
occlusion of CVCs, mortality, adverse events, etc.). NNTB values
have been calculated from the RR according to the formulaNNTB
(or number needed to treat for an additional harmful outcome
(NNTH)) = 1/ACR*(1-RR), where ACR is the assumed control
risk (McQuay 1997).
Unit of analysis issues
Initially, when the present systematic review was planned, because
of clinical considerations, the unit of analysis was assumed to be
the participant. Once the literature search was performed, three
studies were found wherein the unit of analysis was the catheter,
and in only two studies the unit of analysis was the participant; in
one study the unit of analysis was line access (each time that a line
is used to provide drugs, blood, etc.). In view of this, all studies
were included and analysed separately for each different unit of
analysis.
Dealing with missing data
The principal investigators of two studies (Goosens 2013;
Schallom 2012) were contacted to obtain additional data. They
provided relevant data that were later published.
Assessment of heterogeneity
We attempted to explain relevant clinical, methodological or sta-
tistical heterogeneity using forest plots, and we quantiﬁed hetero-
geneity using the I2 statistic (Higgins 2003).
Assessment of reporting biases
We planned to assess reporting bias by using funnel plots if sufﬁ-
cient numbers of studies were identiﬁed.
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Data synthesis
Data were statistically summarised if available. Statistical analysis
was performed according to the statistical guidelines referenced
in the current version of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).We used ReviewManager
5 for review production and data analysis. We used a ﬁxed-effect
model.
Subgroup analysis and investigation of heterogeneity
The incidence of CVC-related thrombosis varies depending on
the clinical type of the participant (onco-haematological, critical,
on dialysis, etc.), CVC implantation site, CVC type and infusate-
related factors. Subgroup analyses were planned to take these fac-
tors into account, if available.
Sensitivity analysis
Sensitivity analyses were carried out to explore the inﬂuence of the
following factors on effect size.
• Published or unpublished studies.
• Quality of studies.
• Weight of different studies.
Robustness of results was assessed using differentmeasures of effect
size (OR and RR).
R E S U L T S
Description of studies
Only randomised controlled trials of heparin ﬂushing versus ﬂush-
ing with 0.9%NaCl (normal saline) sterile solution in adults were
included.
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
Included studies
Six studies met the predeﬁned inclusion criteria (Bowers 2008;
Goosens 2013; Kaneko 2004; Pumarola 2007; Rabe 2002;
Schallom 2012). These studies included a combined total of 1433
participants. See Characteristics of included studies.
Bowers 2008 conducted a single-centre randomised study in 102
adult participants with single-lumen peripherally inserted central
catheters (PICCs) with luer-activated devices. Participants were
randomly assigned by means of a random block design with allo-
cation concealment to receive 0.9% NaCl sterile solution (NS) or
heparin lock ﬂush (100 USP U/mL). All participants completed
the study (50 in the NS group and 52 in the heparin group). The
main outcome studied was occlusion rate, and the secondary out-
come was duration of PICCs (in days).
Goosens 2013 conducted a randomised controlled open-label
non-inferiority trial in 802 participants older than one year, sched-
uled for a ﬁrst totally implantable venous access device (TIVAD)
insertion through the superior vena cava (SVC) system, with
an onco-haematological malignancy and with sufﬁcient life ex-
pectancy to complete the planned follow-up of 180 days at the
study centre. After randomisation by means of computerised ran-
dom number generation, 398 were assigned to receive an NS lock
and 404 were assigned to receive a heparin lock in a non-blinded
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manner. Although participants were randomly assigned, the unit
of analysis was the number of catheters accessed. Outcomes con-
sidered were withdrawal of obstruction, catheter-related bacter-
aemia and catheter duration within 180 days, as well as adverse
events. Data on sepsis, thrombosis and mortality were also pro-
vided.
Kaneko 2004 performed a single-centre, open-label, randomised
controlled clinical trial in adult participants with an inserted dou-
ble-lumen CVC. This study compared a ﬂush of 20 mL NS ver-
sus a ﬂush of 20 mL NS followed by locking with 2 mL heparin
(1000 IU/mL). Low molecular weight heparin was used during
each haemodialysis session at 8 IU/kg/h. Forty-eight participants
were randomly allocated to the NS (26) or heparin group (22).
Outcomes studied were days of catheter survival and thrombotic
occlusion, as well as coagulation analytical parameters such as acti-
vated coagulation time, activated partial thromboplastin time and
prothrombin time.
Pumarola 2007 carried out a two-phase clinical trial in a polyva-
lent ICU. Participants were adults with multiple pathological pro-
cesses in whom a three-lumen CVC had been inserted. Randomi-
sation was provided by means of a registered software (Aleator®).
However, the study was not blinded. In a ﬁrst phase, two concen-
trations of heparin (100 IU/5 mL and 500 IU/5 mL) were com-
pared, establishing patency at 24 hours after catheter implantation
and at discharge. In a second phase, heparin at a concentration of
100 IU/mL was compared with NS, and patency was assessed at
24 hours, at 72 hours and at discharge. Only this second phase
fulﬁlled our inclusion criteria. Ninety-ﬁve CVCs were assessed in
this phase-38 in the heparin group and 57 in the NS group-for
occlusion rates and mean days of catheter duration.
Rabe 2002 studied 99 three-lumen CVCs inserted in 91 adult
participants locked with one of the following solutions: NS, hep-
arin (5000 IU/mL) or vitamin C (200 mg/mL). Catheters were
assigned randomly (by means of a list of random numbers pre-
pared by the study authors) to one of three groups. Patency was
assessed every two days to a maximum of 20 days. Study outcomes
included thrombotic obstruction and catheter survival.
Schallom 2012 conducted a single-centre study wherein patients
in the ICU with a newly placed three- or four-lumen CVC were
randomly assigned (simple randomisation, sequence concealed) to
be ﬂushed with NS or with heparin (10 IU/mL every 8 hours).
Among the randomly assigned participants, 295 had at least one
lumen with a minimum of two ﬂushes, resulting in 326 catheters
(170 pertaining to the NS group and 156 to the heparin group)
with 709 lumens-395 in the NS group and 314 in the heparin
group. The primary outcome was lack of lumen patency. Sec-
ondary outcomes included rates of loss of blood return, ﬂush
failure, heparin-induced thrombocytopaenia and catheter-related
bloodstream infection.
Excluded studies
A total of 316 studies did not fulﬁl inclusion criteria and were
excluded. Reasons for exclusion can be found in theCharacteristics
of excluded studies section.
Among 2080 studies identiﬁed after duplicates and ongoing clin-
ical trials were removed, 1757 were found not relevant. A total of
316 full-text articles were excluded for the following reasons.
• 75 studies were not randomised controlled trials.
• 152 studies did not meet the criteria established for
intervention (heparin) or comparison (0.9% NaCl sterile
solution).
• 37 studies did not meet the criteria established for
outcomes reported.
• 70 studies did not meet the criteria established for
participants.
• 21 studies focused on peripheral catheters.
• 9 studies focused on arterial catheters.
Some articles were excluded for more than one reason.
Risk of bias in included studies
Figure 2 and Figure 3 show risk of bias according to the quality of
included trials.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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We did not create funnel plots for assessment of publication bias
for primary outcomes because of the low number of included
studies.
Summarising risk of bias for the outcomes: occlusion
of CVCs, CVC-related thrombosis, CVC-related
sepsis, mortality and haemorrhage across domains
Occlusion of CVCs
Unit of analysis: participant
Two trials (Bowers 2008; Kaneko 2004) assessed this outcome.
Bowers 2008 was judged to be of low risk of bias for random
sequence generation, but Kaneko 2004 was rated as unclear risk of
bias for random sequence generation. Both were rated as unclear
risk of bias for allocation concealment. Both studies were rated as
low risk of bias in the domain of blinding and appear to be free of
other bias. We believe that the risk of bias for this outcome is low.
Unit of analysis: catheter
The three trials that assessed this outcome (Pumarola 2007; Rabe
2002; Schallom 2012) were rated as low risk of bias for random
sequence generation, but two studies (Pumarola 2007; Rabe 2002)
were rated as unclear risk of bias for allocation concealment. All
three studieswere rated as low risk of bias in the domain of blinding
and appear free of other bias. Despite the fact that Pumarola 2007
was stopped early, we judge that the risk of bias for this outcome
is low.
Unit of analysis: line access
One trial (Goosens 2013) assessed this outcome. Goosens 2013
was judged to be at low risk of bias for all domains except attrition
bias and other bias, as the study insufﬁciently reported exclusions.
However, we believe this does not affect this outcome; therefore
we judge that risk of bias for this outcome is low.
CVC-related thrombosis
The two trials assessing this outcome (Goosens 2013; Schallom
2012) were rated as low risk for random sequence generation,
allocation concealment and blinding. Therefore, we judge the risk
of bias for this outcome to be low.
CVC-related sepsis
The two trials assessing this outcome (Goosens 2013; Schallom
2012) were rated as low risk for random sequence generation,
allocation concealment and blinding. Therefore, we judge the risk
of bias for this outcome to be low.
Mortality
The three trials that assessed this outcome (Goosens 2013; Kaneko
2004; Pumarola 2007) were rated as having different risks of bias
for the main domains. Goosens 2013 was at low risk of bias for all
main domains, Pumarola 2007 was judged to be at unclear risk of
bias for allocation concealment and Kaneko 2004 was judged to
be at unclear risk of bias for random sequence generation and al-
location concealment. However Kaneko 2004 reported no deaths;
therefore we believe that the risk of bias for this outcome is low.
Haemorrhage across domains
Three trials (Goosens 2013; Kaneko 2004; Schallom 2012) as-
sessed this outcome. Only Kaneko 2004 was rated as unclear risk
of bias for the domains of random sequence generation and allo-
cation concealment. Goosens 2013 and Schallom 2012 were rated
as low risk of bias for the domains of random sequence generation,
allocation concealment and blinding. Therefore we judge the risk
of bias for this outcome to be low.
Allocation
All studies (Bowers 2008; Goosens 2013; Pumarola 2007; Rabe
2002; Schallom2012) speciﬁed the procedure of random sequence
generation, except for one (Kaneko 2004). Bowers 2008 used a
permuted block sequence, whereas Goosens 2013, Rabe 2002 and
Schallom 2012 used a list of random numbers, leading to a sim-
ple randomisation procedure. Pumarola 2007 randomly assigned
participants by using a registered software (Aleator®).
Allocation concealment was not reported in three studies (Bowers
2008; Kaneko 2004; Rabe 2002), rendering the risk of selec-
tion bias unclear. Three studies speciﬁed allocation concealment:
Pumarola 2007 used a method of closed envelopes, but it remains
unclear whether the envelopes were opaque or sealed to conceal in-
formation; Goosens 2013 concealed the allocation sequence from
researchers who enrolled participants by using sequentially num-
bered participant cards stored in a separate room; Schallom 2012
stated that the allocation sequence was concealed from the re-
searcher enrolling participants.
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Blinding
Although none of the included studies was blinded, neither occlu-
sion nor time to occlusion was likely to be inﬂuenced by lack of
blinding. Some secondary outcomes of the present systematic re-
view may be inﬂuenced by lack of blinding, namely, CVC-related
thrombosis, episodes of CVC-related sepsis and colonisation, but
the secondary outcomes of number of additional CVC insertions,
mortality, coagulation proﬁle, HIT, allergic reactions to heparin
and haemorrhage were not so inﬂuenced.
Incomplete outcome data
All (Bowers 2008; Kaneko 2004; Pumarola 2007; Schallom 2012)
but two (Goosens 2013; Rabe 2002) included studies were con-
sidered to have low risk of attrition bias because missing outcome
data were balanced in numbers across intervention groups, with
similar reasons for missing data across groups. In the Rabe 2002
and Goosens 2013 studies, reporting of attrition or exclusions
was insufﬁcient to permit judgement, and information about the
number of catheters losing patency in each treatment group was
lacking in Rabe 2002. For this reason, a criterion of unclear risk
of bias was assigned to Goosens 2013 and Rabe 2002.
Selective reporting
All studies that were considered were classiﬁed as having low risk
of reporting bias. Although the study protocols were not available,
it was clear that published reports included all expected outcomes,
including those that were prespeciﬁed.
Other potential sources of bias
The study conducted by Pumarola 2007 may be underpowered.
Only 38 and 57 catheters per group were analysed, but prede-
termined sample size was 185 catheters per group; the study was
stopped early for 74 and52 catheters in the heparin andNSgroups,
respectively. Risk of other bias was therefore high. In Goosens
2013, 3.5% of participants were children, but no separate analyses
of children and adults were conducted; therefore the risk of other
bias was unclear. The remaining studies were at low risk of other
bias.
Effects of interventions
See: Summary of findings for the main comparison Heparin
for central venous catheters
Primary outcomes
Occlusion of CVCs
• Two studies were focused on participant as unit of analysis
(Bowers 2008; Kaneko 2004), including 76 participants.
Findings are pooled in Figure 4. Analysis performed using a
Mantel-Haenszel (M-H) ﬁxed-effect model yielded an RR of
0.21 (95% CI 0.03 to 1.70) (i.e. a non-signiﬁcant effect), with
heterogeneity of I2 = 0.
Figure 4. Forest plot of comparison: 1 Occlusion of CVCs, outcome: 1.1 Occlusion of CVCs (unit of analysis
participant).
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• Three studies were focused on catheter as unit of analysis
(Pumarola 2007; Rabe 2002; Schallom 2012), totaling 1025
observations. Findings are pooled in Figure 5, demonstrating a
favourable effect of heparin when results were analysed by means
of an M-H ﬁxed-effect model (RR 0.53, 95% CI 0.29 to 0.94, P
value 0.03). No heterogeneity among studies was noted (I2 =
0%), speaking well for statistical comparability of studies. The
NNTB calculated according to the McQuay method (McQuay
1997) was 35 (95% CI 23 to 273).
Figure 5. Forest plot of comparison: 1 Occlusion of CVCs, outcome: 1.2 Occlusion of CVCs (unit of analysis
catheter).
• Only one study was focused on line access as unit of analysis
(Goosens 2013). This study included 6137 observations and
showed no differences between heparin and NS (RR 1.08, 95%
CI 0.84 to 1.40) (Figure 6).
Figure 6. Forest plot of comparison: 1 Occlusion of CVCs, outcome: 1.3 Occlusion of CVCs (unit of analysis
line access).
Duration (in days) of catheter patency
• Three studies (Bowers 2008; Goosens 2013; Kaneko 2004)
in whom unit of analysis was the participant were analysed and
pooled for catheter patency duration. Mean difference analysis
revealed no signiﬁcant differences between heparin and NS (MD
0.41, 95% CI -1.29 to 2.12). Heterogeneity was found to be
very low (I2 = 0%).
• Two studies (Pumarola 2007; Schallom 2012) analysed
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catheter patency using catheter as unit of analysis. The mean
difference plot shows no statistical differences between heparin
and NS groups (MD 0.40, 95% CI -0.20 to 0.99).
Heterogeneity was found to be very low (I2 = 0%).
Secondary outcomes
See additional Table 1.
CVC-related thrombosis
Only Schallom 2012 and Goosens 2013 reported incidences of
CVC-related thrombosis. Schallom 2012 found 10.7% venous
thromboembolisms in the NS group (16 participants) and 13.1%
(19 participants) in the heparin group (X2 = 0.419, P value 0.518),
showing no statistical differences between groups. Goosens 2013
found retrospectively a conﬁrmed diagnosis of central venous
thrombosis in 13 participants (3.3%) in the heparin group and
in 11 participants (2.8%) in the NS group (X2 = 0.060, P value
0.807). Pooled results showed non-signiﬁcant differences between
heparin and NS groups through an M-H ﬁxed-effect model (RR
1.22; 95% CI 0.74 to 1.99; Analysis 3.1). Low heterogeneity was
noted among studies (I2 = 0%).
Episodes of CVC-related sepsis and CVC-related
colonisation
Two studies were focused on sepsis (Goosens 2013; Schallom
2012) and showed a non-signiﬁcant effect by using anM-H ﬁxed-
effect model (RR 1.02, 95% CI 0.34 to 3.03; Analysis 3.2). Het-
erogeneity among studies was high (I2 = 75%).
In Schallom 2012, four participants in the saline group experi-
enced episodes of CVC-related sepsis or colonisation compared
with none in the heparin group. All four participants were given
non-antibiotic-impregnated catheters. This difference was not sta-
tistically signiﬁcant (X2 = 2.180, P value 0.140, Yates correc-
tion applied). In Goosens 2013, catheter-related bacteraemia was
found in two out of 404 cases (0.5%) in the NS group and in six
out of 398 cases (1.5%) in the heparin group (P value 0.18).
Number of additional CVC insertions
No data were provided.
Mortality
Three studies were focused on mortality (Goosens 2013; Kaneko
2004; Pumarola 2007), showing a non-signiﬁcant effect by using
an M-H ﬁxed-effect model (RR 0.77, 95% CI 0.45 to 1.32;
Analysis 3.3). Heterogeneity among studies was low (I2 = 0%).
No deaths were reported in the study of Kaneko 2004, three were
reported in Pumarola 2007 (two in the heparin group and one in
the NS group, without signiﬁcant differences) and 48 in Goosens
2013 (28 in the NS group and 20 in the heparin group; P value
0.255). No other included studies reported mortality.
Abnormality of coagulation profile
Only Kaneko 2004 reported alterations in coagulation parame-
ters. These investigators studied activated coagulation time (ACT),
activated partial thromboplastin time (APTT) and prothrombin
time (PT).Kaneko 2004 founddifferences between the twogroups
for both ACT (P value < 0.001) and APTT (P value 0.001). In
particular, said parameters, except PT (P value 0.187), were higher
in the heparin group. Differences observed in the PT parameter,
which was elevated in the heparin group, did not reach statistical
signiﬁcance.
Allergic reactions to heparin
No data were provided.
Heparin-induced thrombocytopaenia
OnlyKaneko 2004 and Schallom 2012 reportedHIT, but whereas
Kaneko 2004 found no cases of HIT, Schallom 2012 detected two
cases, both in the NS group (Analysis 3.5; RR 0.21, CI 95% 0.01
to 4.27). These latter cases may be due, in our opinion, to systemic
anticoagulation with heparin.
Haemorrhage from any site in the body
Goosens 2013, Kaneko 2004 and Schallom2012 studied bleeding
likely associated with heparin, using an M-H ﬁxed-effect model
(RR 1.37, 95% CI 0.49 to 3.85; Analysis 3.4). Heterogeneity
among studies was low (I2 = 0%). Goosens 2013 reported no
haemorrhages in any group. Kaneko 2004 reported oozing from
the exit site of the dialysis catheter in ﬁve participants in the heparin
group and in ﬁve in the NS group with no statistically signiﬁcant
differences (X2 = 0.088, P value 0.799). In Schallom 2012, one
participant presented with bleeding in the heparin group versus
none in the NS group (X2 = 0, P value 0.984, Yates correction).
Subgroup analysis
We planned to do subgroup analyses but were unable to do so
because of lack of data.
Sensitivity analysis
We planned to carry out sensitivity analyses for published versus
unpublished studies, quality of studies and weight of studies, as
well as for OR versus RR.
The only study initially identiﬁed as an unpublished study was
Goosens 2013, but this study was later published, and no other
unpublished studies were identiﬁed.
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The quality of the included studies was found to be very similar,
and sensitivity analyses were deemed not relevant.
All outcomes (both primary and secondary) were explored to anal-
yse the effect of each particular study on the aggregated results.
Not one outcome (occlusion of CVCs with unit of analysis the
participant, occlusion of CVCs with unit of analysis line access,
duration of catheter patency, CVC-related thrombosis, CVC-re-
lated sepsis, mortality, haemorrhage from any site, HIT) was sen-
sitive to removal of any of the included studies, except for occlu-
sion of CVCs when the unit of analysis was the catheter. In this
case, when the trial with the greatest weight (Schallom 2012) was
removed, the RR changed substantially (RR 0.33, 95% CI 0.10 to
1.12), making the difference between heparin and normal saline
no longer signiﬁcant.
Differences between OR and RR were explored and calculated,
but these were found to be not signiﬁcant.
D I S C U S S I O N
Summary of main results
The aim of the present review was to assess the effectiveness of
intermittent ﬂushing with heparin versus 0.9% sodium chloride
(normal saline) solution in adults with central venous catheters in
terms of prevention of occlusion and overall beneﬁts versus harms.
Central venous catheters are frequently used in patients to provide
blood derivatives, medication or nutritional support, as well as
for diagnostic monitoring, cardiac pacing or other procedures.
However, their use could result in thrombosis and infection and
may prolong hospital stay.
We found no conclusive evidence of important differences when
intermittent ﬂushing with heparin versus 0.9% normal saline for
central venous catheter maintenance was compared, in terms of
efﬁcacy or safety. The quality of the evidence was very low to
moderate. As heparin is more expensive than normal saline, our
ﬁndings challenge its continued use in CVC ﬂushing outside the
context of clinical trials.
Overall completeness and applicability of
evidence
All of the addressed outcomes have been analysed. Statistical het-
erogeneity was low (I2 = 0) for the main outcomes of efﬁcacy
(obstruction, patency) and safety (bleeding, thrombosis and mor-
tality), despite inclusion of participants with very different con-
ditions (critical, with onco-haematological malignancies or un-
der haemodialysis), who were treated with a very wide range of
heparin concentrations ranging from 30 IU/mL to 2500 IU/mL.
Only sepsis showed signiﬁcant statistical heterogeneity (I2 = 75%),
which could be explained by the different clinical conditions of
included participants.
None of the studies showed statistically signiﬁcant differences in
any of the focused outcomes. It must be noted, in this respect, that
CVC occlusion showed a statistically signiﬁcant difference when
the unit of analysis was the catheter; notwithstanding this obser-
vation, the fact that no differences were observed when the unit of
analysis was the participant or lines accessed, together with lack of
effect in survival catheter time when the unit of analysis was the
catheter or the participant, suggests that no real differences were
noted between groups. Our results disagree with those of a retro-
spective cohort study by Jonker 2010, which detected increased
use of alteplase to clean catheters ﬂushed with NS compared with
catheters locked with heparin. However these results may be bi-
ased by the indirectness of outcomes.
It is interesting to consider also the use of systemic anticoagulants
in the different studies. In Pumarola 2007 and Goosens 2013, the
use of any anticoagulation was a criterion of exclusion; although
no data were stated in Bowers 2008. Kaneko 2004, Rabe 2002
and Schallom 2012 on permitted use of systemic anticoagulation
in every participant (Kaneko 2004) or in only some participants
(Rabe 2002, Schallom 2012), differences were found to be not
signiﬁcant.
The length of follow-up for safety in this review could be too short
to reveal relevant adverse events. Only Goosens 2013 provided
long-term follow-up (180 days), whereas Pumarola 2007, Rabe
2002 and Schallom 2012 studied participants only for a short
time, andBowers 2008 andKaneko 2004 studied participants for a
period ranging from40 to 50 days. Consequently, the potential for
higher incidence with long-term follow-up cannot be discarded.
Given that CVCs could be placed for several months according to
the needs of patients, adverse events may be more relevant than
those described in the present systematic review. None of the six
included trials was planned to study adverse events.Moreover, two
arms in all trials were too few. In summary, it cannot be ruled
out that adverse events may occur with longer exposure or higher
numbers of participants.
Despite results suggesting no differences, it is probable that a high
proportion of patients could be at increased risk with heparin
use. This increased risk of adverse events due to heparin ﬂushing
may be especially relevant among patients with liver or kidney
failure and those with recent surgery (especially of the brain, eye
or spine), spinal anaesthesia or recent injury. Also patients who
have a history of heart problems, high blood pressure, menstrual
problems, bleeding problems, a history of ulcers or other stomach
problems, or who are taking drugs such as non-steroidal anti-
inﬂammatory drugs or antiplatelet agents, may have increased risk
of bleeding. Adverse events may be reduced by ﬂushes with NS.
Heparin-induced thrombocytopaenia (HIT) is an adverse event
that may be life threatening. It is more common after intraoper-
ative or perioperative administration of heparin. Its incidence is
reported at between 0.1% and 5%. Risk factors for HIT include
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type of heparin (greater risk with unfractionated heparin), dura-
tion of exposure, patient setting and patient gender (1.5 to 2 times
higher in women) (Battistelli 2010). In general, higher doses of
heparin result in greater risk of HIT. However, lower heparin doses
used to ﬂush catheters have occasionally been associated with HIT
(McNulty 2005). In the present systematic review, HIT was not
reported in the heparin groups, and only two cases were reported
in the NS groups (Schallom 2012), suggesting an altogether un-
diagnosed adverse event. Nevertheless, routine use of NS instead
of heparin may reduce HIT.
Quality of the evidence
The main results are described in Summary of ﬁndings for the
main comparison. The quality of the evidence ranged from very
low to high.
The quality of the evidence for the main outcome (occlusion of
CVC) ranged from very low to low to high, according to the unit
of analysis. Differences were found only when the unit of analysis
was the catheter. It must be noted that results were sensitive to
removal of the trial with the greatest weight (Schallom 2012) (RR
0.33, 95% CI 0.10 to 1.12), so they must be interpreted with
caution. When the study with the lowest quality was not taken
into account (Pumarola 2007), the results remained unchanged
because this trial reported no events in both arms.
Duration of catheter patency was the second main outcome, and
its quality of evidence was rated as low when the unit of analysis
was the catheter or the participant. This outcome did not show
statistical differences in terms of means of days for patency. Results
did not change when the largest trials in both analyses were taken
into account (with unit of analysis being the catheter and unit of
analysis being the participant) (Goosens 2013; Schallom 2012)
(MD 0.32, 95% CI -2.37 to 3.01, and MD 0.62, 95% CI -1.17
to 2.42, respectively).
Potential biases in the review process
Study selection and data extraction were carried out in dupli-
cate manner. A protocol was published for this systematic review
(López-Briz 2010). All outcomes analysed were selected a priori.
The unit of analysis initially selected was the participant. The
other units of analysis used-catheter and lines accessed-were added
a posteriori. Trial authors were contacted, and additional infor-
mation was retrieved, hence the probability of publication bias of
this systematic review is low. Although we could not absolutely
discard bias from non-published studies, contact with authors of
the latest published studies and continued search of clinical trials
registers led us to believe that risk of publication bias was low.
Agreements and disagreements with other
studies or reviews
Other systematic reviews have focused on heparin use in CVCs
using different inclusion and/or exclusion criteria from those of
this review. Randolph 1998b reviewed randomised controlled tri-
als in adult and paediatric study participants in whom heparin was
infused continuously through the catheter, administered subcuta-
neously (SC) or bonded to the catheter. They found only a trend
toward reduction of catheter thrombus and a signiﬁcant reduction
(57%) in venous thrombosis. Statistical heterogeneity was not sig-
niﬁcant in both cases. Heparin dosage ranged from SC 5000 IU
every 12 hours to 1 IU/mL in continuous perfusion added to total
parenteral nutrition.
Klerk 2003 also reviewed adult and paediatric study participants
with CVCs in whom heparin ﬂushes or antithrombotic agents
were administered in prophylactic or therapeutic doses. This study
concluded that the addition of heparin to parenteral nutrition did
not signiﬁcantly decrease the risk of catheter-related thrombosis.
However this review cannot be compared with the present one
because it differs in the design of included studies (randomised
controlled trials and prospective cohort studies) and in the inter-
vention provided (systemic heparin).
In a previous systematic review (López-Briz 2005) by some of the
authors of this Cochrane review, only two studies were included,
one of which was conducted in paediatric participants. Results
showed no differences between heparin and NS ﬂush.
Mitchell 2009 conducted a systematic review focused on adult
study participants with CVCs or PICCs comparing heparin ﬂush-
ing, heparin continuous perfusion, NS ﬂushing, urokinase ﬂush-
ing and heparin-bonded catheter versus any other intervention. As
a result of heterogeneity of interventions and comparisons, results
of the review are difﬁcult to understand.
In paediatric participants, Shah 2008 found that continuous hep-
arin infusion reduced the risk of catheter occlusion with no sta-
tistically signiﬁcant differences in the duration of catheter pa-
tency. However, recommendations for heparin use in neonates
with PICCs could not be made. The review authors detected high
clinical heterogeneity and high heterogeneity in treatment effect.
Guidelines have led to a wide variety of ﬂushing protocols, with
many different types of ﬂushing solution, volumes, ﬂushing fre-
quencies and heparin concentrations (Mitchell 2009; Sona 2012).
This is due to the fact that they are basedmainly onmanufacturers’
recommendations-not on published evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, heparin ﬂushing of CVCs is a recommended practice
in many guidelines and is standard practice in many clinical care
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settings, notwithstanding the fact that it is not supported by any
strong evidence. The present systematic review conﬁrms that no
conclusive evidence shows important differences when heparin in-
termittent ﬂushing was compared with 0.9% normal saline ﬂush-
ing in central venous catheter maintenance, in terms of efﬁcacy
or safety. As heparin is more expensive than normal saline, our
ﬁndings challenge its continued use in CVC ﬂushing outside the
context of clinical trials.
Implications for research
Better designed, large-scale randomised controlled trials are
needed to deﬁnitively establish or rule out a net beneﬁt of ﬂushing
with heparin versus 0.9% NaCl (normal saline). More trials may
be needed to address whether this practice could be effective in
selected patients, such as patients under haemodialysis or those
with onco-haematological malignancies. Different units of analy-
sis (catheters, accesses) could have diminished the impact of ﬁnd-
ings of the two large trials (Goosens 2013; Schallom 2012), mak-
ing them not directly comparable. On the other hand, whether
this practice causes harm requires trials or observational studies
speciﬁcally designed for safety with sufﬁcient duration of follow-
up.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bowers 2008
Methods Randomised open-label controlled trial
Participants 102 participants with single-lumen peripherally inserted central catheters (PICCs) with
luer-activated devices
Interventions Flushing with:
• Heparin 100 IU/mL ﬂushing (3 mL)
• 0.9% sodium chloride ﬂushing (10 mL)
Outcomes Occlusion of PICCs, average duration of catheter
Notes Follow-up until the ﬁrst of the following: event (occlusion) or discharge
No data on use of systemic anticoagulation, as stated by study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A random block design with concealment
was used”
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to permit judge-
ment. Method of concealment is not de-
scribed or is not described in sufﬁcient detail
to allow a deﬁnitive judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Open-label trial, but the outcome is not likely
to be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of outcome assessment, but out-
come measurement is not likely to be inﬂu-
enced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers
across intervention groups, with similar rea-
sons for missing data across groups
Selective reporting (reporting bias) Low risk Study protocol is not available, but it is clear
that published reports include all expected
outcomes, including those that were prespec-
iﬁed
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Bowers 2008 (Continued)
Other bias Low risk Study appears to be free of other sources of
bias
Goosens 2013
Methods Randomised open-label non-inferiority controlled trial
Participants 802 participants older than 1 year with an onco-haematological malignancy
Interventions Flushing with:
• 10 mL 0.9% NaCl and after 3 mL heparin (100 IU/mL)
• 10 mL 0.9% NaCl
Outcomes Primary outcome: withdrawal occlusion at access (i.e. inability to aspirate blood while
injection is easy)
Secondary outcomes: catheter-related bacteraemia within 180 days, duration of catheter
Notes Follow-up 180 days
Following contact with the trialists, we obtained additional raw data, which have been
used in the analysis
Use of heparin IV was an exclusion criterion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation computer generated
Allocation concealment (selection bias) Low risk Allocation concealment by means of se-
quentially numbered participant cards,
stored in a separate room
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded, but the outcome is categorical
(blood aspiration possible or not) and is not
likely to be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded, but the outcome is categorical
(blood aspiration possible or not) and is not
likely to be inﬂuenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reporting of attrition/exclusions insufﬁ-
cient to permit judgement: no information
on number of catheters losing patency in
each group
40Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Goosens 2013 (Continued)
Selective reporting (reporting bias) Low risk All prespeciﬁed outcomes of the study were
reported in the prespeciﬁed way
Other bias Unclear risk No separate analyses for children (3.5%)
and adults.Not enough information toper-
mit judgement of other bias
Kaneko 2004
Methods Randomised open-label controlled trial
Participants 48 participants under haemodialysis with double-lumen central venous catheter
Interventions Flushing with:
• 20 mL 0.9% NaCL+ 2 mL heparin 1000 IU/mL lock
• 20 mL 0.9% NaCl
Outcomes Thrombotic occlusion, catheter survival, catheter patency time, haematological and co-
agulation markers, safety
Notes Low molecular weight heparin (dalteparin, parnaparin or reviparin) was used during
each haemodialysis session
Follow-up not clearly reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information about sequence generation pro-
cess insufﬁcient to permit judgement
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to permit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Outcome not likely to be inﬂuenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of outcome assessment, but out-
come measurement is not likely to be inﬂu-
enced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers
across intervention groups, with similar rea-
sons for missing data across groups
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Kaneko 2004 (Continued)
Selective reporting (reporting bias) Low risk Study protocol is not available, but it is clear
that published reports include all expected
outcomes, including those that were prespec-
iﬁed
Other bias Low risk Study appears to be free of other sources of
bias
Pumarola 2007
Methods Randomised blinded controlled trial
Participants 250 patients in intensive care unit (ICU) with 3-lumen central venous catheter
Interventions Flushing with:
• 5 mL 0.9% NaCl
• 5 mL heparin 20 IU/mL
Outcomes Catheter patency at 24 hours, at 72 hours and at discharge from ICU (mean 4.74, SD
5)
Notes 2-Phase trial: In the ﬁrst phase, 2 different dosages of heparin were compared; in the
second phase, heparin was compared with 0.9% NaCl
Follow-up until ﬁrst of the following: event (occlusion) or discharge
Systemic anticoagulant use was exclusion criterion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation computer generated (software
Aleator®)
Allocation concealment (selection bias) Unclear risk Information was insufﬁcient to permit judge-
ment. Method of concealment is not described
or is not described in sufﬁcient detail to allow a
deﬁnitive judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Open-label trial, but the outcome is not likely to
be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of outcome assessment, but out-
come measurement is not likely to be inﬂuenced
by lack of blinding
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Pumarola 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers
across intervention groups, with similar reasons
for missing data across groups
Selective reporting (reporting bias) Low risk Study protocol is not available, but it is clear that
published reports include all expected outcomes,
including those that were prespeciﬁed
Other bias High risk Study may be underpowered: Only 38 and 57
participants per group were analysed, but pre-
determined sample size was 185 participants per
group. Study was stopped early in 74 partici-
pants pertaining to the heparin group and in 52
participants pertaining to the 0.9% NaCl group
Rabe 2002
Methods Randomised open-label controlled trial
Participants 91 intensive care unit patients in whom 99 3-lumen central venous catheters were im-
planted
Interventions Catheter lock with 0.5 mL of:
• Heparin 5000 IU/mL
• 0.9% NaCl
• Vitamin C 200 mg/mL
Outcomes Catheter patency (tested every 2 days)
Notes Follow-up 20 days
Prophylactic or therapeutic anticoagulation was used in the 3 groups but with non-
signiﬁcant differences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list prepared by study authors
using a random number generator
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to permit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Open-label trial, but the outcome is not likely
to be inﬂuenced by lack of blinding
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Rabe 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of outcome assessment, but out-
come measurement is not likely to be inﬂu-
enced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reporting of attrition/exclusions insufﬁcient
to permit judgement: no information about
number of catheters losing patency in each
group
Selective reporting (reporting bias) Low risk Study protocol is not available, but it is clear
that published reports include all expected
outcomes, including those that were prespec-
iﬁed
Other bias Low risk Study appears to be free of other sources of
bias
Schallom 2012
Methods Randomised controlled open-label trial
Participants 295 patients (326 catheters, 709 lumens) from medical or surgical intensive care unit in
whom a 3- or 4-lumen central venous catheter was inserted
Interventions Flushes every 8 hours with:
• 3 mL heparin 10 IU/mL
• 10 mL 0.9% NaCl
Outcomes Rate of lumennon-patency, blood loss return, ﬂush failure, rate of catheter-related blood-
stream infection, heparin-induced thrombocytopaenia
Notes Follow-up 22 days
Prophylactic or therapeutic anticoagulation was used in both groups with non-signiﬁcant
differences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Investigators used a computerised random
number generator in MS Excel®
Allocation concealment (selection bias) Low risk “The allocation sequence was concealed until
the card was retrieved upon obtaining patient
consent”
Follow-up 1-27 days
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Schallom 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Outcome not likely to be inﬂuenced by lack
of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of outcome assessment, but out-
come measurement is not likely to be inﬂu-
enced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers
across intervention groups, with similar rea-
sons for missing data across groups
Selective reporting (reporting bias) Low risk Study protocol is not available, but it is clear
that published reports include all expected
outcomes, including those that were prespec-
iﬁed
Other bias Low risk Study appears to be free of other sources of
bias
ICU: intensive care unit.
PICCs: peripherally inserted central catheters.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AACCN 1993 Arterial catheters were used
Abbas 2009 Study is not an RCT
Abdelkeﬁ 2004 Interventions do not fulﬁl inclusion criteria (continuous infusion)
Abdelkeﬁ 2005 Interventions do not fulﬁl inclusion criteria (continuous infusion); outcomes do not fulﬁl inclusion
criteria (infection)
Abdelkeﬁ 2005a Interventions do not fulﬁl inclusion criteria (heparin-coated catheters)
Abdelkeﬁ 2007 Interventions do not fulﬁl inclusion criteria (heparin-bonded catheter + normal saline vs non-
coated catheter + continuous infusion heparin)
Abdelkeﬁ 2008 Interventions do not fulﬁl inclusion criteria (impregnated catheters)
Agnelli 2009 Interventions do not fulﬁl inclusion criteria (systemic nadroparin)
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Akyuz 2010 Comparison does not fulﬁl inclusion criteria (heparin vs taurolidine + citrate)
Alexander 2010 Peripheral catheters were used
Alpan 1984 Participants do not fulﬁl inclusion criteria (children)
Andersen 1992 Study is not an RCT
Ankola 1993 Arterial catheters were used; interventions do not fulﬁl inclusion criteria
Anton 2009 Participants and intervention do not fulﬁl inclusion criteria (children, heparin-bonded catheters)
Appelgren 1995 Study is not an RCT
Appelgren 1996 Interventions do not fulﬁl inclusion criteria (heparin-bonded catheters)
Aquino 2002 Interventions do not fulﬁl inclusion criteria (urokinase ﬂushes), outcomes do not fulﬁl inclusion
criteria (prevention of bacteraemia)
Araujo 2008 Interventions do not fulﬁl inclusion criteria (catheter comparison)
Arnts 2011 Peripheral catheters were used. Participants do not fulﬁl inclusion criteria (neonates)
Arone 2012 Study is not an RCT
Arrants 1999 Interventions do not fulﬁl inclusion criteria (saline lock only), outcomes do not fulﬁl inclusion
criteria (obtaining blood samples)
Ashton 1990 Peripheral catheters were used
Aslam 2008 Study is not an RCT
Aslam 2010 Study is not an RCT
Aslam 2011 Comparisons do not fulﬁl inclusion criteria (heparin or citrate vs heparin + tigecycline + N-
acetylcysteine)
Bailey 1979 Interventions do not fulﬁl inclusion criteria (continuous perfusion of heparin), outcomes do not
fulﬁl inclusion criteria (sepsis prevention)
Balduini 2010 Peripheral catheters were used
Baltrons 2008 Study is not an RCT (retrospective study)
Barrett 1990 Interventions do not fulﬁl inclusion criteria (peripheral catheters)
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Barriga 1997 Interventions do not fulﬁl inclusion criteria (heparin with or without vancomycin), outcomes do
not fulﬁl inclusion criteria (prevention of bacteraemia)
Bayes 1999 Study is not an RCT
Beecroft 1997 Participants do not fulﬁl inclusion criteria (children)
Bennegard 1982 Interventions do not fulﬁl inclusion criteria (heparin-coated vs non-coated catheters)
Bertoglio 2012 Study is not an RCT
Bertolino 2012 Peripheral catheters were used
Betjes 2004 Comparison does not fulﬁl inclusion criteria (heparin vs citrate-taurolidine), outcomes do not fulﬁl
inclusion criteria (prevention of sepsis)
Betremieux 1988 Participants do not fulﬁl inclusion criteria (children)
Birch 2010 Participants do not fulﬁl inclusion criteria (neonates)
Bisseling 2010 Comparison does not fulﬁl inclusion criteria (heparin vs taurolidine)
Bleyer 2005 Comparison interventions do not fulﬁl inclusion criteria (heparin vs minocycline + EDTA)
Bolgiano 1990 Arterial catheters were used
Bookstaver 2009 Study is not an RCT
Bossert 1994 Study is not an RCT
Bracho-Blanchet 2010 Participants do not fulﬁl inclusion criteria (children)
Branger 2011 Interventions do not fulﬁl inclusion criteria (arteriovenous ﬁstula vs tunnelled jugular vein catheter)
Branson 1993 Comparison interventions do not fulﬁl inclusion criteria (heparin vs sodium citrate)
Brismar 1982 Interventions do not fulﬁl inclusion criteria (systemic heparin)
Broom 2009 Comparison interventions do not fulﬁl inclusion criteria (heparin vs ethanol), outcomes do not
fulﬁl inclusion criteria (prevention of infection)
Broom 2012 Outcomes do not fulﬁl inclusion criteria (prevention of infection)
Brown-Smith 1990 Study is not an RCT
Butt 1987 Arterial catheters were used
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Buturovic 1998 Comparison interventions do not fulﬁl inclusion criteria (heparin vs citrate vs polygeline)
Cabrita 2011 Study is not an RCT
Calderero 2009 Study is not an RCT
Campbell 2011 Participants do not fulﬁl inclusion criteria (children)
Campos 2011 Comparison interventions do not fulﬁl inclusion criteria (heparin vs ethanol). Outcomes do not
fulﬁl inclusion criteria (catheter-related bacteraemia)
Cardinal 2000 Outcomes do not fulﬁl inclusion criteria (acid-base and electrolyte measurements)
Carrasco 2004 Interventions do not fulﬁl inclusion criteria (heparin-coated catheter)
Carratala 1999 Interventions do not fulﬁl inclusion criteria (heparin vs heparin + vancomycin), outcomes do not
fulﬁl inclusion criteria (prevention of infection)
Carrero 2012 Study is not an RCT
Casale 2009 Comparisons do not fulﬁl inclusion criteria (comparison of 2 heparin concentrations)
Catorze 2011 Arterial catheters were used
Catton 2006 Peripheral catheters were used
Cesaro 2009 Participants do not fulﬁl inclusion criteria (paediatric participants)
Chang 1997 Outcomes do not fulﬁl inclusion criteria (intraventricular haemorrhage ratio)
Cheronis 2013 Comparisons do not fulﬁl inclusion criteria (heparin vs trimetoprim + EDTA + ethanol)
Chu 2009 Comparisons do not fulﬁl inclusion criteria (heparin vs heparin + gentamicin)
Clark 2009 Study is not an RCT
Clifton 1991 Interventions do not fulﬁl inclusion criteria (heparin continuous ﬂush)
Coli 2006 Interventions do not fulﬁl inclusion criteria (oral anticoagulant drugs)
Conte 2003 Interventions do not fulﬁl inclusion criteria (systemic low molecular weight heparin)
Coplon 2007 Comparisons do not fulﬁl inclusion criteria (heparin vs gentamicin + citrate)
Corbett 2013 Comparisons do not fulﬁl inclusion criteria (heparin vs taurolidine + heparin + citrate)
Cortes 2006 Comparisons do not fulﬁl inclusion criteria (heparin vs minocycline + EDTA)
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Cottee 1995 Study is not an RCT
Crews 1997 Participants do not fulﬁl inclusion criteria (paediatric participants)
Daghistani 1996 Participants do not fulﬁl inclusion criteria (children)
Danek 1992 Participants do not fulﬁl inclusion criteria (children)
Daniell 1973 Interventions do not fulﬁl inclusion criteria (warfarin vs low molecular weight heparin)
Davanipur 2011 Comparison does not fulﬁl inclusion criteria (heparin vs cloxacillin + heparin). Outcomes do not
fulﬁl inclusion criteria (prevention of infection)
David 1981 Participants do not fulﬁl inclusion criteria (children)
De Cicco 2009 Interventions do not fulﬁl inclusion criteria (acenocumarine vs dalteparin vs no treatment)
de la Torre 2012 Peripheral catheters were used
de Neef 2002 Participants do not fulﬁl inclusion criteria (children)
del Cotillo 2008 Interventions do not fulﬁl inclusion criteria (arterial catheters)
del Pozo 2012 Interventions do not fulﬁl inclusion criteria (comparison of antibiotic concentrations)
Dias 2000 Participants do not fulﬁl inclusion criteria (children)
Dillon 2004 Participants do not fulﬁl inclusion criteria (children), comparison interventions do not fulﬁl inclu-
sion criteria (heparin vs urokinase)
Dogra 2002 Comparison interventions donot fulﬁl inclusion criteria (heparin vs gentamicin + citrate), outcomes
do not fulﬁl inclusion criteria (prevention of infection)
Donham 1987 Peripheral catheters were used
Duemichen 2012 Participants do not fulﬁl inclusion criteria (children). Comparison interventions do not fulﬁl
inclusion criteria (heparin vs taurolidine). Outcomes do not fulﬁl inclusion criteria (prevention of
infection)
Duncan 2005 Comparison interventions do not fulﬁl inclusion criteria (heparin vs citrate)
Duncan 2010 Comparisons do not fulﬁl inclusion criteria (heparin vs taurolidine)
Dunser 2005 Interventions do not fulﬁl inclusion criteria (coated vs non-coated catheters), outcomes do not
fulﬁl inclusion criteria (prevention of infection)
Dupuis 2012 Study is not an RCT, comparison interventions do not fulﬁl inclusion criteria (heparin vs citrate)
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Edstrom 2002 Participants do not fulﬁl inclusion criteria (children), outcomes do not fulﬁl inclusion criteria
(analytical determinations)
Eloy 1987 Interventions do not fulﬁl inclusion criteria (catheter comparison)
Epperson 1984 Interventions do not fulﬁl inclusion criteria (peripheral catheters)
Everts 2004 Study is not an RCT
Ferreira 2011 Participants do not fulﬁl inclusion criteria (children)
Festini 2013 Participants do not fulﬁl inclusion criteria (children) (peripheral catheters)
Filippi 2007 Participants do not fulﬁl inclusion criteria (children), interventions do not fulﬁl inclusion criteria
(heparin + fusidic acid), outcomes do not fulﬁl inclusion criteria (prevention of infection)
Fonseca 2010 Study is not an RCT
Fort 2011 Participants do not fulﬁl inclusion criteria (children)
Fratino 2002 Participants do not fulﬁl inclusion criteria (children)
Garay Rubio 2011 Peripheral catheters were used
Garland 2005 Participants do not fulﬁl inclusion criteria (neonates), comparison interventions do not fulﬁl in-
clusion criteria (heparin vs heparin + vancomycin), outcomes do not fulﬁl inclusion criteria (pre-
vention of infection)
Garrelts 1989 Peripheral catheters were used
Gillies 1985 Study is not an RCT
Gittins 2007 Participants do not fulﬁl inclusion criteria (children), comparison interventions do not fulﬁl inclu-
sion criteria (heparin vs alteplase)
Glaspy 2000 Interventions do not fulﬁl inclusion criteria (systemic dalteparin)
Goh 2011 Interventions do not fulﬁl inclusion criteria (IV continuous heparin administration)
Golberg 1999 Participants do not fulﬁl inclusion criteria (neonates)
Gomez Palomar 2005 Study is not an RCT
Goode 1993 Peripheral catheters were used
Grifﬁn 2005 Interventions do not fulﬁl inclusion criteria (papaverine)
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Grosso 1989 Interventions do not fulﬁl inclusion criteria (calcium heparin)
Guillet 1997 Study is not an RCT
Gyr 1995 Interventions do not fulﬁl inclusion criteria (peripheral catheters)
Hall 2006 Interventions do not fulﬁl inclusion criteria (continuous ﬂush), outcomes do not fulﬁl inclusion
criteria (platelet count)
Hamilton 1988 Peripheral catheters were used
Handrup 2012 Comparison interventions do not fulﬁl inclusion criteria (heparin vs taurolidine). Participants do
not fulﬁl inclusion criteria (children)
Handrup 2013 Participants do not fulﬁl inclusion criteria (children)
Hanrahan 1994 Participants do not fulﬁl inclusion criteria (children)
Harlev 2010 Participants do not fulﬁl inclusion criteria (children)
Harter 2002 Interventions do not fulﬁl inclusion criteria (coated vs non-coated catheters), outcomes do not
fulﬁl inclusion criteria (prevention of infection)
Haynes 2002 Interventions do not fulﬁl inclusion criteria (SC device)
Heilskov 1998 Participants do not fulﬁl inclusion criteria (neonates)
Hemmelgarn 2006 Study is not an RCT
Hemmelgarn 2011 Comparison interventions do not fulﬁl inclusion criteria (heparin vs alteplase)
Hendrickx 2001 Comparison interventions do not fulﬁl inclusion criteria (citrate vs heparin)
Heng 2011 Interventions do not fulﬁl inclusion criteria (ethanol lock)
Henrickson 2000 Participants do not fulﬁl inclusion criteria (children), outcomes do not fulﬁl inclusion criteria
(prevention of infection)
HGU Gregorio Marañón 2010 Comparisons do not fulﬁl inclusion criteria (heparin vs ethanol)
Hill 2011 Participants do not fulﬁl inclusion criteria (children)
Hoffer 1999 Interventions do not fulﬁl inclusion criteria (valved vs non-valved catheters)
Hook 1987 Study is not an RCT
Horgan 1987 Participants do not fulﬁl inclusion criteria (infants)
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Horne 1995 Comparison interventions do not fulﬁl inclusion criteria (heparin vs lepirudin)
Horne 2006 Study is not an RCT
Hryszko 2013 Comparisons do not fulﬁl inclusion criteria (comparison of 2 heparin concentrations)
Hu 2011 Comparisons do not fulﬁl inclusion criteria (comparison of 2 heparin concentrations)
Imamovic 2009 Comparisons do not fulﬁl inclusion criteria (heparin vs citrate)
Ishii 2013 Interventions do not fulﬁl inclusion criteria (heparin continuous administration)
Israel Ministry of Health Comparisons do not fulﬁl inclusion criteria (heparin vs taurolidine)
Jaksic 2010 Comparisons do not fulﬁl inclusion criteria (heparin vs ethanol). Participants do not fulﬁl inclusion
criteria (children)
James 1994 Study is not an RCT
Jasinsky 2007 Interventions do not fulﬁl inclusion criteria (antireﬂux device)
Jeppesen 2013 Comparisons do not fulﬁl inclusion criteria (heparin vs taurolidine)
Johnson 2002 Interventions do not fulﬁl inclusion criteria (mupirocin), outcomes do not fulﬁl inclusion criteria
(prevention of infection)
Jonker 2010 Study is not an RCT (retrospective cohort)
Jonkers 2012 Comparison interventions do not fulﬁl inclusion criteria (heparin vs taurolidine)
Jowett 1986 Peripheral catheters were used
Kalmanti 2002 Study is not an RCT, participants do not fulﬁl inclusion criteria (children)
Kamala 2002 Participants do not fulﬁl inclusion criteria (neonates)
Kankanala 2012 Comparison does not fulﬁl inclusion criteria (heparin vs citrate)
Karthaus 2006 Interventions do not fulﬁl inclusion criteria (systemic dalteparin)
Kleiber 1993 Participants do not fulﬁl inclusion criteria (children)
Klenner 2003 Participants do not fulﬁl inclusion criteria (children)
Knoﬂer 1999 Study is not an RCT, participants do not fulﬁl inclusion criteria (children)
Kokenge 2010 Comparison does not fulﬁl inclusion criteria (heparin vs citrate)
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Kotter 1996 Participants do not fulﬁl inclusion criteria (neonates)
Kovacs 2005 Interventions do not fulﬁl inclusion criteria (systemic dalteparin)
Krafte-Jacobs 1995 Participants do not fulﬁl inclusion criteria (children)
Kristinsson 1985 Study is not an RCT
Kudsk 1985 Interventions do not fulﬁl inclusion criteria (heparin administered in continuous perfusion)
Kulkarni 1994 Interventions do not fulﬁl inclusion criteria (continuous ﬂush)
Kyle 1999 Study is not an RCT
Lacasaña Bellmunt 2006 Peripheral catheters were used
Lavau-Denes 2013 Interventions do not fulﬁl inclusion criteria (warfarin vs low molecular weight heparin)
Le 2003 Interventions do not fulﬁl inclusion criteria (dressings)
LeDuc 1997 Participants do not fulﬁl inclusion criteria (children)
Lee 2006 Study is not an RCT
Lenhart 2001 Study is not an RCT
Leslie 1996 Comparisons do not fulﬁl inclusion criteria (comparison of 2 heparin concentrations)
Liang 1998 Peripheral catheters were used
Liao 2002 Peripheral catheters were used
Lindblad 1994 Interventions do not fulﬁl inclusion criteria (systemic heparin), outcomes do not fulﬁl inclusion
criteria (anticoagulation)
Lok 2007 Comparison interventions do not fulﬁl inclusion criteria (heparin vs sodium citrate)
Lombardi 1988 Participants do not fulﬁl inclusion criteria (children)
Long 2006 Interventions do not fulﬁl inclusion criteria (heparin-bonded catheters)
Lustig 2011 Comparisons do not fulﬁl inclusion criteria (heparin vs citrate + ethanol + methylene blue)
Macrae 2008 Comparison does not fulﬁl inclusion criteria (heparin vs citrate)
Maki 2011 Comparison interventions do not fulﬁl inclusion criteria (heparin vs sodium citrate + methylene
blue + methylparaben + propylparaben)
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Male 2005 Study is not an RCT
Malo 2010 Comparison interventions do not fulﬁl inclusion criteria (heparin vs tinzaparin)
Marin 2000 Interventions do not fulﬁl inclusion criteria (heparin-bonded catheters), outcomes do not fulﬁl
inclusion criteria (prevention of infection)
Martin 2009 Participants do not fulﬁl inclusion criteria (children). Interventions do not fulﬁl inclusion criteria
(ethanol vs heparin)
Masroujeh 2008 Study is not an RCT
Massicotte 1996 Participants do not fulﬁl inclusion criteria (children)
Massicotte 2003 Interventions do not fulﬁl inclusion criteria (systemic raveparin), participants do not fulﬁl inclusion
criteria (children)
Mayo 1996 Study is not an RCT
McIntyre 2004 Comparison interventions do not fulﬁl inclusion criteria (heparin vs heparin + gentamicin), out-
comes do not fulﬁl inclusion criteria (prevention of infection)
McMullen 1993 Interventions do not fulﬁl inclusion criteria (peripheral catheters), participants do not fulﬁl inclu-
sion criteria (children)
Meier 2011 Interventions do not fulﬁl inclusion criteria (catheter comparison)
Mendarte 1997 Study is not an RCT
Meyer 1995 Interventions do not fulﬁl inclusion criteria (peripheral catheters)
Meyer 2010 Participants do not fulﬁl inclusion criteria (children)
Mismetti 2003 Interventions do not fulﬁl inclusion criteria (systemic dalteparin), comparison interventions do
not fulﬁl inclusion criteria (warfarin)
Mitchell 2003 Participants do not fulﬁl inclusion criteria (children)
Mok 2007 Participants do not fulﬁl inclusion criteria (children)
Monreal 1996 Interventions do not fulﬁl inclusion criteria (systemic nadroparin)
Moran 2012 Comparison interventions do not fulﬁl inclusion criteria (gentamicin + citrate vs heparin)
Mortazavi 2011 Comparison interventions do not fulﬁl inclusion criteria (heparin vs heparin + cefotaxime), out-
comes do not fulﬁl inclusion criteria (prevention of infection)
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Mudge 1998 Interventions do not fulﬁl inclusion criteria (peripheral catheters)
Myrianthefs 2005 Study is not an RCT
Na 2012 Arterial catheters were used
Niers 2007 Interventions do not fulﬁl inclusion criteria (systemic nadroparin)
Niesen 2003 Interventions do not fulﬁl inclusion criteria (peripheral catheters)
Nieto-Rodriguez 1992 Peripheral catheters were used
NIH Clinical Centers 2002 Comparisons do not fulﬁl inclusion criteria (heparin vs lepirudin)
Nori 2006 Comparison does not fulﬁl inclusion criteria (gentamicin vs minocycline). Outcomes do not fulﬁl
inclusion criteria (prevention of infection)
Ociepa 2010 Participants do not fulﬁl inclusion criteria (children)
Oguzhan 2012 Interventions do not fulﬁl inclusion criteria (heparin + NaCl 26% vs heparin)
Ojala 2007 Study is not an RCT
Onder 2009 Study is not an RCT
Oran 2008 Comparison interventions do not fulﬁl inclusion criteria (heparin lock 3 times a week vs heparin
lock 6 times a week)
Paisley 1997 Participants do not fulﬁl inclusion criteria (children)
Periard 2008 Interventions do not fulﬁl inclusion criteria (catheter comparison)
Pervez 2002 Comparison interventions do not fulﬁl inclusion criteria (heparin vs sodium citrate + gentamicin)
, outcomes do not fulﬁl inclusion criteria (prevention of infection)
Petersen 2001 Study is not an RCT
Pierce 2000 Participants do not fulﬁl inclusion criteria (children)
Pouw 1995 Interventions do not fulﬁl inclusion criteria (systemic heparin)
Power 2009 Comparison interventions do not fulﬁl inclusion criteria (heparin vs citrate)
Powers 1999 Outcomes do not fulﬁl inclusion criteria (analytical results)
Pucheu 1996 Study is not an RCT
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Puiggros 2012 Study is not an RCT
Quenot 2013 Comparisons do not fulﬁl inclusion criteria (heparin vs citrate)
Rackoff 1995 Particpants do not fulﬁl inclusion criteria (children), comparison interventions do not fulﬁl inclu-
sion criteria (heparin vs heparin + vancomycin), outcomes do not fulﬁl inclusion criteria (preven-
tion of infection)
Rajani 1979 Interventions do not fulﬁl inclusion criteria (warfarin vs low molecular weight heparin)
Randon 2006 Comparisons do not fulﬁl inclusion criteria (heparin vs non-needle system)
Rao 1981 Participants do not fulﬁl inclusion criteria (children)
Ray 1999 Comparison interventions do not fulﬁl inclusion criteria (heparin vs urokinase)
Reeves 2009 Participants do not fulﬁl inclusion criteria (neonates)
Reichardt 2002 Interventions do not fulﬁl inclusion criteria (systemic heparin)
Renaud 2009 Study is not an RCT
Rijnders 2005 Interventions do not fulﬁl inclusion criteria (antibiotics vs placebo)
Roberts 1994 Peripheral catheters were used
Robertson 1994 Participants do not fulﬁl inclusion criteria (children)
Robinson 2009 Study is not an RCT
Ruggiero 1983 Interventions do not fulﬁl inclusion criteria (heparin continuous)
Sahin Balcik 2011 Study is not an RCT
Sanders 2008 Comparison interventions do not fulﬁl inclusion criteria (heparin vs ethanol), outcomes do not
fulﬁl inclusion criteria (prevention of infection)
Sang Sook 2012 Arterial catheters were used
Saxena 2005 Study is not an RCT
Saxena 2006 Comparison does not fulﬁl inclusion criteria (heparin vs cefotaxime + heparin)
Saxena 2006a Comparison does not fulﬁl inclusion criteria (heparin vs cefotaxime + heparin)
Scherr 2002 Arterial catheters were used
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(Continued)
Schilling 2006 Participants do not fulﬁl inclusion criteria (children)
Schouten 2013 Comparisons do not fulﬁl inclusion criteria (heparin vs citrate)
Schroder 2008 Comparisons do not fulﬁl inclusion criteria (heparin vs taurolidine)
Schroeder 2010 Participants do not fulﬁl inclusion criteria (infants)
Schultz 2002 Participants do not fulﬁl inclusion criteria (children)
Schwartz 1990 Participants do not fulﬁl inclusion criteria (children), outcomes do not fulﬁl inclusion criteria
(prevention of infection)
Seguin 1994 Study is not an RCT
Seliem 2010 Participants do not fulﬁl inclusion criteria (children)
Serrano 2009 Study is not an RCT
Shah 2007a Participants do not fulﬁl inclusion criteria (neonates)
Shen 2013 Study is not an RCT
Shirzad 2013 Comparisons do not fulﬁl inclusion criteria (heparin vs heparin + cefazolin)
Shively 1997 Study is not an RCT
Shoaf 1992 Study is not an RCT
Sierra 2010 Study is not an RCT
Silva 2008 Interventions do not fulﬁl inclusion criteria (antibiotic ointment vs antibiotic lock)
Silva 2013 Comparison does not fulﬁl inclusion criteria (heparin vs heparin + cefazolin + gentamicin)
Skoﬁc 2009 Study is not an RCT
Smith 1990 Interventions do not fulﬁl inclusion criteria (heparin lock left in place)
Smith 1991 Study is not an RCT, participants do not fulﬁl inclusion criteria (neonates)
Sofroniadou 2012 Comparison does not fulﬁl inclusion criteria (heparin vs heparin + vancomycin vs heparin +
linezolid)
Solomon 2001 Comparison does not fulﬁl inclusion criteria (heparin vs urokinase)
Solomon 2010 Comparison does not fulﬁl inclusion criteria (heparin vs taurolidine + citrate)
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(Continued)
Solomon 2012 Study is not an RCT
Sona 2012 Study is not an RCT
Stas 2001 Comparison does not fulﬁl inclusion criteria (heparin vs citrate)
Steczko 2009 Study is not an RCT
Stephens 1997 Study is not an RCT
Taylor 1989 Participants do not fulﬁl inclusion criteria (children)
Thomson 2011 Comparison interventions do not fulﬁl inclusion criteria (different concentrations of heparin)
Thurlimann 1992 Interventions do not fulﬁl inclusion criteria (peripheral catheters)
Tolar 1996 Interventions do not fulﬁl inclusion criteria (no heparin use)
Treas 1992 Participants do not fulﬁl inclusion criteria (children)
Trivedi 1997 Study is not an RCT
Trottier 1995 Interventions do not fulﬁl inclusion criteria (different catheterisation sites)
Tuncali 2005 Interventions do not fulﬁl inclusion criteria (arterial catheters, continuous ﬂushing)
Tuten 1991 Peripheral catheters were used
Unal 2012 Participants do not fulﬁl inclusion criteria (children)
Uslu 2010 Partoicipants and interventions do not fulﬁl inclusion criteria (children, heparin continuous infu-
sion)
Van Rooden 2004 Study is not an RCT
Vegting 2012 Study is not an RCT
Venditto 2010 Comparison interventions do not fulﬁl inclusion criteria (heparin vs citrate vs heparin + gentamicin)
Vercaigne 2011 Comparisons do not fulﬁl inclusion criteria (heparin vs citrate + ethanol)
Verso 2005 Interventions do not fulﬁl inclusion criteria (systemic enoxaparin)
Verso 2008 Study is not an RCT
Vertrees 2001 Study is not an RCT
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(Continued)
Wan 2012 Study is not an RCT
Wang 2012 Peripheral catheters were used
Warkentin 1998 Outcomes do not fulﬁl inclusion criteria (formation of hepatin antibodies)
Wassenaar 2008 Study is not an RCT
Weijmer 2005 Comparison does not fulﬁl inclusion criteria (heparin vs citrate)
White 2011 Participants do not fulﬁl inclusion criteria (children)
Whitta 2006 Interventions do not fulﬁl inclusion criteria (continuous heparin ﬂushing)
Willicombe 2010 Study is not an RCT
Winnett 2008 Study is not an RCT
Witkovski 2010 Arterial catheters were used
Wolf 2011 Comparisons do not fulﬁl inclusion criteria (heparin vs ethanol)
Wolley 2010 Study is not an RCT
Wong 2009 Outcomes do not fulﬁl inclusion criteria (changes in activated partial thromboplastin time)
Wooldridge 1988 Study is not an RCT
Worly 2004 Study is not an RCT, participants do not fulﬁl inclusion criteria (children)
Wright 1995 Participants do not fulﬁl inclusion criteria (children)
Yevzlin 2007 Study is not an RCT, outcomes do not fulﬁl inclusion criteria (bleeding complications)
Yilmaz 2010 Study is not an RCT
Yon 2013 Study is not an RCT, interventions do not fulﬁl inclusion criteria (citrate vs heparin)
Young 2009 Interventions do not fulﬁl inclusion criteria (warfarin)
Zacharski 2005 Interventions do not fulﬁl inclusion criteria (warfarin vs low molecular weight heparin)
Zhang 2009 Interventions do not fulﬁl inclusion criteria (heparin vs gentamicin + heparin), outcomes do not
fulﬁl inclusion criteria (infection)
EDTA: ethylenediaminetetraacetic acid.
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RCT: randomised controlled trial.
SC: subcutaneous.
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D A T A A N D A N A L Y S E S
Comparison 1. Occlusion of CVCs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occlusion of CVCs (unit of
analysis participant)
2 150 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.03, 1.70]
2 Occlusion of CVCs (unit of
analysis catheter)
3 1025 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.29, 0.94]
3 Occlusion of CVCs (unit of
analysis line access)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Duration of catheter patency
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Duration of catheter patency
(unit of analysis participant)
3 952 Mean Difference (IV, Fixed, 95% CI) 0.41 [-1.29, 2.12]
2 Duration of catheter patency
(unit of analysis catheter)
2 752 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.20, 0.99]
Comparison 3. Safety
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CVC-related thrombosis 2 1097 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.74, 1.99]
2 CVC-related sepsis 2 1097 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.34, 3.03]
3 Mortality 3 1100 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.45, 1.32]
4 Haemorrhage from any site 3 1145 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.49, 3.85]
5 Heparin-induced
thrombocytopaenia
2 343 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.27]
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Analysis 1.1. Comparison 1 Occlusion of CVCs, Outcome 1 Occlusion of CVCs (unit of analysis participant).
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 1 Occlusion of CVCs
Outcome: 1 Occlusion of CVCs (unit of analysis participant)
Study or subgroup Heparin 0.9% NaCl Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bowers 2008 0/52 3/50 72.1 % 0.14 [ 0.01, 2.60 ]
Kaneko 2004 0/22 1/26 27.9 % 0.39 [ 0.02, 9.15 ]
Total (95% CI) 74 76 100.0 % 0.21 [ 0.03, 1.70 ]
Total events: 0 (Heparin), 4 (0.9% NaCl)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours heparin Favours 0.9% NaCl
Analysis 1.2. Comparison 1 Occlusion of CVCs, Outcome 2 Occlusion of CVCs (unit of analysis catheter).
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 1 Occlusion of CVCs
Outcome: 2 Occlusion of CVCs (unit of analysis catheter)
Study or subgroup Heparin 0.9% NaCl Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pumarola 2007 0/125 0/125 Not estimable
Rabe 2002 3/33 9/33 28.9 % 0.33 [ 0.10, 1.12 ]
Schallom 2012 12/314 25/395 71.1 % 0.60 [ 0.31, 1.18 ]
Total (95% CI) 472 553 100.0 % 0.53 [ 0.29, 0.94 ]
Total events: 15 (Heparin), 34 (0.9% NaCl)
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours heparin Favours 0.9% NaCl
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Analysis 1.3. Comparison 1 Occlusion of CVCs, Outcome 3 Occlusion of CVCs (unit of analysis line access).
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 1 Occlusion of CVCs
Outcome: 3 Occlusion of CVCs (unit of analysis line access)
Study or subgroup Heparin 0.9% NaCl Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goosens 2013 115/3026 109/3111 1.08 [ 0.84, 1.40 ]
0.01 0.1 1 10 100
Favours heparin Favours 0.9% NaCl
63Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Duration of catheter patency, Outcome 1 Duration of catheter patency (unit of
analysis participant).
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 2 Duration of catheter patency
Outcome: 1 Duration of catheter patency (unit of analysis participant)
Study or subgroup Heparin 0.9% NaCl
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bowers 2008 52 2.9 (5.7) 50 2.1 (4) 80.1 % 0.80 [ -1.11, 2.71 ]
Goosens 2013 398 150.9 (40.7) 404 152.4 (37.9) 9.8 % -1.50 [ -6.94, 3.94 ]
Kaneko 2004 22 17.3 (8.85) 26 18.1 (10.15) 10.1 % -0.80 [ -6.18, 4.58 ]
Total (95% CI) 472 480 100.0 % 0.41 [ -1.29, 2.12 ]
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours heparin Favours 0.9% NaCl
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Analysis 2.2. Comparison 2 Duration of catheter patency, Outcome 2 Duration of catheter patency (unit of
analysis catheter).
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 2 Duration of catheter patency
Outcome: 2 Duration of catheter patency (unit of analysis catheter)
Study or subgroup Heparin 0.9% NaCl
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pumarola 2007 25 4.87 (5) 18 4.55 (4) 4.9 % 0.32 [ -2.37, 3.01 ]
Schallom 2012 314 8 (4) 395 7.6 (4.3) 95.1 % 0.40 [ -0.21, 1.01 ]
Total (95% CI) 339 413 100.0 % 0.40 [ -0.20, 0.99 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours heparin Favours 0.9% NaCl
Analysis 3.1. Comparison 3 Safety, Outcome 1 CVC-related thrombosis.
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 3 Safety
Outcome: 1 CVC-related thrombosis
Study or subgroup Heparin 0.9% NaCl Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goosens 2013 13/398 11/404 41.0 % 1.20 [ 0.54, 2.65 ]
Schallom 2012 19/145 16/150 59.0 % 1.23 [ 0.66, 2.29 ]
Total (95% CI) 543 554 100.0 % 1.22 [ 0.74, 1.99 ]
Total events: 32 (Heparin), 27 (0.9% NaCl)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours heparin Favours 0.9% NaCl
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Analysis 3.2. Comparison 3 Safety, Outcome 2 CVC-related sepsis.
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 3 Safety
Outcome: 2 CVC-related sepsis
Study or subgroup Heparin 0.9% NaCl Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goosens 2013 (1) 6/398 2/404 31.0 % 3.05 [ 0.62, 15.00 ]
Schallom 2012 0/145 4/150 69.0 % 0.11 [ 0.01, 2.12 ]
Total (95% CI) 543 554 100.0 % 1.02 [ 0.34, 3.03 ]
Total events: 6 (Heparin), 6 (0.9% NaCl)
Heterogeneity: Chi2 = 3.96, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours heparin Favours 0.9% NaCl
(1) Staphylococcus aureus 2, Staphylococcus epidermidis 3, Candida glabatra 1 in Heparin group and Staphylococcus epidermidis 1 and
Staphylococcus homini 1 in saline groups
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Analysis 3.3. Comparison 3 Safety, Outcome 3 Mortality.
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 3 Safety
Outcome: 3 Mortality
Study or subgroup Heparin 0.9% NaCl Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goosens 2013 20/398 28/404 96.5 % 0.73 [ 0.42, 1.27 ]
Kaneko 2004 0/22 0/26 Not estimable
Pumarola 2007 2/125 1/125 3.5 % 2.00 [ 0.18, 21.78 ]
Total (95% CI) 545 555 100.0 % 0.77 [ 0.45, 1.32 ]
Total events: 22 (Heparin), 29 (0.9% NaCl)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours heparin Favours 0.9% NaCl
Analysis 3.4. Comparison 3 Safety, Outcome 4 Haemorrhage from any site.
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 3 Safety
Outcome: 4 Haemorrhage from any site
Study or subgroup Heparin 0.9% NaCl Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goosens 2013 0/398 0/404 Not estimable
Kaneko 2004 5/22 5/26 90.3 % 1.18 [ 0.39, 3.56 ]
Schallom 2012 1/145 0/150 9.7 % 3.10 [ 0.13, 75.55 ]
Total (95% CI) 565 580 100.0 % 1.37 [ 0.49, 3.85 ]
Total events: 6 (Heparin), 5 (0.9% NaCl)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours heparin Favours 0.9% NaCl
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Analysis 3.5. Comparison 3 Safety, Outcome 5 Heparin-induced thrombocytopaenia.
Review: Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults
Comparison: 3 Safety
Outcome: 5 Heparin-induced thrombocytopaenia
Study or subgroup Heparin 0.9% NaCl Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaneko 2004 0/22 0/26 Not estimable
Schallom 2012 0/145 2/150 100.0 % 0.21 [ 0.01, 4.27 ]
Total (95% CI) 167 176 100.0 % 0.21 [ 0.01, 4.27 ]
Total events: 0 (Heparin), 2 (0.9% NaCl)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours heparin Favours 0.9% NaCl
A D D I T I O N A L T A B L E S
Table 1. Secondary outcomes
Study CVC-related
thrombosis
CVC-related
sepsis
Mortality Coagulation pa-
rameters
HIT Haemorhage
H NS H NS H NS H NS H NS H NS
Bowers
2008
NR NR NR NR NR NR NR NR NR NR NR NR
Goosens
2013
13/398 11/404 6/398 2/404 20/398 28/404 NR NR NR NR 0 0
Kaneko
2004
NR NR NR NR 0 0 ACT
in-
ACT
un-
0 0 5/22 5/26
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Table 1. Secondary outcomes (Continued)
creased*
APTT
in-
creased†
PT in-
creased‡
changed
APTT
un-
changed
PT un-
changed
Pumarola
2007
NR NR NR NR 2/125 1/125 NR NR NR NR NR NR
Rabe
2002
NR NR NR NR NR NR NR NR NR NR NR NR
Schal-
lom
2012
19/145 16/150 0/145 4/150 NR NR NR NR 0/145 2/150 1/145 0/150
ACT: activated coagulation time.
APTT: activated partial thromboplastin time.
CVC: central venous catheter.
H: heparin.
HIT: heparin-induced thrombocytopaenia.
NR: not reported.
NS: normal saline (0.9% NaCl).
PT: prothrombin time.
*P value < 0.001 for comparison with NS group; †P value 0.001 for comparison with NS group; ‡Non-signiﬁcant difference for
comparison with NS group (P value 0.187).
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Heparin] explode all trees 3995
#2 (hep* or UH or UFH or LMWH):ti,ab,kw 26525
#3 MeSH descriptor: [Sodium Chloride] this term only 1757
#4 MeSH descriptor: [Saline Solution, Hypertonic] explode all
trees
360
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(Continued)
#5 saline*:ti,ab,kw 13508
#6 sodium:ti,ab,kw 19429
#7 NaCl:ti,ab,kw 1189
#8 #1 or #2 26756
#9 #3 or #4 or #5 or #6 or #7 31063
#10 #8 and #9 1030
#11 MeSH descriptor: [Catheterization, Central Venous] this term
only
721
#12 MeSH descriptor: [Catheterization] this term only 1415
#13 MeSH descriptor: [Catheters, Indwelling] explode all trees 908
#14 catheter*:ti,ab,kw 11675
#15 cannula*:ti,ab,kw 1456
#16 CVC* or PICC:ti,ab,kw 273
#17 venous near/3 access 318
#18 #11 or #12 or #13 or #14 or #15 or #16 or #17 12715
#19 #10 and #18 in Trials 128
Appendix 2. MEDLINE search strategy
Database: Ovid MEDLINE(R) <1946 to November Week 3 2013>
Search strategy:
--------------------------------------------------------------------------------
1 exp Heparin/ (57389)
2 (hep$ or UH or UFH or LMWH).ti,ab. (627845)
3 Sodium Chloride/ (50802)
4 Saline Solution, Hypertonic/ (5000)
5 saline.ti,ab. (131343)
6 sodium.ti,ab. (261605)
7 NaCl.ti,ab. (44546)
8 1 or 2 (644714)
9 or/3-7 (440904)
10 8 and 9 (21343)
11 Catheterization, Central Venous/ (11904)
12 Catheterization/ (46418)
13 Catheters, Indwelling/ (16134)
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14 cannul$.ti,ab. (33065)
15 catheter$.ti,ab. (147967)
16 (CVC or PICC).ti,ab. (2879)
17 (venous adj3 access).ti,ab. (3589)
18 or/11-17 (208806)
19 10 and 18 (1058)
20 randomized controlled trial.pt. (390995)
21 controlled clinical trial.pt. (90070)
22 randomized.ab. (288395)
23 placebo.ab. (157299)
24 clinical trials as topic.sh. (175750)
25 randomly.ab. (200079)
26 trial.ti. (124923)
27 or/20-26 (897019)
28 exp animals/ not humans.sh. (4066609)
29 27 not 28 (826166)
30 19 and 29 (120)
Appendix 3. EMBASE search strategy
Database: Embase <1980 to 2013 Week 50>
Search strategy:
--------------------------------------------------------------------------------
1 exp heparin/ (111566)
2 (hep$ or UH or UFH or LMWH).ti,ab. (773397)
3 1 or 2 (830780)
4 sodium chloride/ (119646)
5 hypertonic solution/ (4892)
6 (saline or sodium or NaCl).ti,ab. (487934)
7 or/3-6 (1333259)
8 3 and 7 (830780)
9 central venous catheterization/ (7513)
10 catheterization/ (36817)
11 catheter thrombosis/pc [Prevention] (183)
12 intravenous catheter/ or catheter/ or peripherally inserted central venous catheter/ (36105)
13 (catheter$ or cannul$).ti,ab. (230742)
14 (CVC or PICC).ti,ab. (4479)
15 (venous adj3 access).ti,ab. (5380)
16 or/9-15 (256005)
17 8 and 16 (17487)
18 random$.ti,ab. (864687)
19 factorial$.ti,ab. (22152)
20 (crossover$ or cross over$ or cross-over$).ti,ab. (68906)
21 placebo$.ti,ab. (198520)
22 (doubl$ adj blind$).ti,ab. (142411)
23 (singl$ adj blind$).ti,ab. (14177)
24 assign$.ti,ab. (235808)
25 allocat$.ti,ab. (81397)
26 volunteer$.ti,ab. (175670)
27 CROSSOVER PROCEDURE/ (39190)
28 DOUBLE-BLIND METHOD/ (119131)
29 RANDOMIZED CONTROLLED TRIALS/ (43057)
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30 SINGLE-BLIND METHOD/ (18632)
31 or/18-30 (1358554)
32 17 and 31 (1879)
Appendix 4. CINAHL search strategy
Interface
- EBSCOhost Research Databases
Search Screen
- Advanced Search
Database
- CINAHL Plus
Search modes
- Find all my search terms
S32 S13 AND S23 AND S31 80
S31 S24OR S25OR S26ORS27OR S28OR
S29 OR S30
40,125
S30 TX venous N3 access 1,007
S29 TX (CVC or PICC) 1,046
S28 TX catheter* 38,099
S27 TX cannul* 2,913
S26 (MH “Catheters”) 2,666
S25 (MH “Catheterization”) 2,725
S24 (MH “Catheterization, Central Venous”) 2,802
S23 S21 AND S22 1,079
S22 S16 OR S17 OR S18 OR S19 OR S20 22,046
S21 S14 OR S15 55,265
S20 TX NaCl 479
S19 TX sodium 15,578
S18 TX saline 7,258
S17 (MH “Saline Solution, Hypertonic”) 586
S16 (MH “Sodium Chloride”) 2,008
S15 TX (hep* or UH or UFH or LMWH) 55,259
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(Continued)
S14 (MH “Heparin+”) 6,072
S13 S1 or S2 or S3 or S4 or S5 or S6 or S7 or
S8 or S9 or S10 or S11 or S12
332,461
S12 single blind 10,305
S11 double blind 31,977
S10 triple blind 227
S9 latin square 267
S8 placebo* 29,457
S7 (MH “Placebos”) 8,466
S6 follow-up stud* 63,187
S5 alloca* 18,840
S4 random* 171,810
S3 clin* N2 trial* 135,194
S2 (MH “Random Assignment”) 36,178
S1 (MH “Clinical Trials+”) 168,712
Appendix 5. Clinicaltrials.gov search
catheter AND heparin 74 studies found
Appendix 6. International Clinical Trials Registry Platform (WHO database)
heparin AND catheter 56 records for 53 trials found
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Appendix 7. Controlled-trials.com search
catheter AND heparin 28
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
When the present systematic review was planned, and as a result of clinical considerations, the unit of analysis was assumed to be the
participant. When the literature search was performed, three studies were found wherein the unit of analysis was the catheter, whereas
in only two studies, the unit of analysis was the participant, and in one study, the unit of analysis was line access (every time that a line
was used to provide drugs, blood, etc.). In view of this, all included studies were analysed separately for each different unit of analysis.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Catheter Obstruction [statistics & numerical data]; ∗Catheterization, Central Venous; ∗Central Venous Catheters; Anticoagulants
[∗administration&dosage];Heparin [∗ administration&dosage]; SodiumChloride [∗ administration&dosage]; Therapeutic Irrigation
[methods]
MeSH check words
Adult; Humans
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